Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
11.23
-0.50 (-4.26%)
At close: Nov 10, 2026, 4:00 PM EST
11.23
0.00 (0.00%)
Pre-market: Nov 11, 2026, 7:49 AM EST
Cullinan Therapeutics Employees
Cullinan Therapeutics had 109 employees as of December 31, 2025. The number of employees decreased by 2 or 1.80% compared to the previous year. That makes Cullinan Therapeutics the 30,898th largest employer in the world and 3,942nd in the United States.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$1,933,101
Market Cap
729.06M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 109 | -2 | -1.80% | 109 | 0 |
| Dec 31, 2024 | 111 | 26 | 30.59% | 111 | 0 |
| Dec 31, 2023 | 85 | 23 | 37.10% | 85 | 0 |
| Dec 31, 2022 | 62 | 31 | 100.00% | 62 | 0 |
| Mar 31, 2022 | 37 | 13 | 54.17% | 37 | 0 |
| Dec 31, 2021 | 31 | 7 | 29.17% | 31 | 0 |
| Sep 30, 2021 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2021 | 28 | 11 | 64.71% | 28 | 0 |
| Mar 31, 2021 | 24 | 7 | 41.18% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Prime Medicine | 146 |
| Sana Biotechnology | 142 |
| Solid Biosciences | 121 |
| Janux Therapeutics | 114 |
| OmniAb | 89 |
| Candel Therapeutics | 55 |
| Arbutus Biopharma | 19 |
CGEM News
- 17 hours ago - Cullinan Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 20 hours ago - Cullinan Therapeutics reports Q3 EPS (74c), consensus (84c) - TheFly
- 1 day ago - Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 1 day ago - Cullinan Therapeutics Earnings release: Q3 2026 - Filings
- 1 day ago - Cullinan Therapeutics Quarterly report: Q3 2026 - Filings
- 1 day ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 days ago - Cullinan announces data from Genrix Bio Phase 1b/2a study of velinotamig - TheFly
- 2 days ago - Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 - GlobeNewsWire